Nurses Lead Toxicity Monitoring in Indolent Lymphoma Care
At SOHO 2025, Lorenzo Falchi, MD, highlighted the critical role of nurses in monitoring and educating patients on toxicities from novel lymphoma therapies.
Osimertinib/Chemo Boosts Survival in Frontline EGFR+ NSCLC
FLAURA2 data show osimertinib plus chemotherapy significantly improves overall survival vs osimertinib alone in frontline EGFR+ advanced NSCLC.
Precision Supportive Care Centers Patient Preference in Oncology
Michelle Kirschner, MSN, RN, ACNP, APRN-BC, discusses how precision supportive care tailors interventions to patient needs.
Lutetium Lu 177 Dotatate Brings Partial Response in Metastatic BP-NETs
Lutetium Li 177 dotatate was linked with partial responses in patients with metastatic bronchopulmonary neuroendocrine tumors, per real-world data.
Safety Management With Amivantamab Plus Lazertinib in NSCLC
Benjamin Besse, MD, PhD, shares AE management strategies with amivantamab/lazertinib in EGFR-positive NSCLC following CHRYSALIS-2 results.
Rx Road Map: Durvalumab for Endometrial Cancer
Read an advanced practice nurse's tips for treating patients with endometrial cancer with durvalumab.
FDA Accepts Relacorilant NDA for Platinum-Resistant Ovarian Cancer
Relicorilant’s new drug application for platinum-resistant ovarian cancer has been accepted by the FDA.
Tepotinib Shows Manageable Safety in MET Exon 14+ NSCLC
Tepotinib was associated with frequent but manageable adverse events in MET exon 14–positive NSCLC, with peripheral edema most common.
Gemcitabine Intravesical System Receives FDA OK for NMIBC
Formerly known as TAR-200, gemcitabine intravesical system has received the FDA’s approval for use in patients with BCG-unresponsive NMIBC.
Adverse Events of Menin Inhibitors in AML: What Nurses Should Know
Ghayas C. Issa, MD, MS, discusses key adverse events of menin inhibitors in NPM1-mutated and KMT2Ar AML.
Ivonescimab/Chemo Ups PFS After Third-Generation TKI in EGFR+ NSCLC
Adding ivonescimab to chemotherapy improved PFS for patients with EGFR-mutated non–small cell lung cancer after treatment with a third-generation TKI.
Proactive Nursing Care for PI3K and AKT Inhibitor Adverse Effects
Expert Kelsey Martin shares nursing insights on balancing glucose control and GI side effects when caring for patients on PI3K and AKT inhibitors.
Subcutaneous Daratumumab Reduces Smoldering Myeloma Progression
New AQUILA data show PFS improvement in patients with smoldering multiple myeloma who were treated with subcutaneous daratumumab vs active monitoring.
Where Is the Care in Health Care?
GLP-1a Associated With Better Outcomes for Those With Polycythemia Vera
Mortality, progression, and venous thromboembolism were among outcomes improved for patients with polycythemia vera taking a GLP-1a.
Structure to Safety: A Nurse's Guide to Safe ADC Care
Familiarity with each component of antibody-drug conjugates helps nurses and APPs deliver proactive adverse event management to patients with cancer.
Venetoclax Combo Did Not Increase OS in Intermediate/High-Risk MDS
Patients with intermediate- or high-risk MDS experienced a higher modified overall response rate with the venetoclax/azacitidine vs placebo/azacitidine.
Monitoring Severe Adverse Effects of Bispecifics in Multiple Myeloma
Lisa Hwa Christenson, DNP, CNP, FAPO, shares best practices for monitoring CRS and ICANS with BCMA bispecific antibodies in community oncology.
Understanding the Unique Roles of Oncology Teams in Biology-Guided RT
Biology-guided radiotherapy involves teamwork across multiple specialists, according to Samantha Bianzon, BSN, RN.
Opinion: Nursing Considerations for Emerging CLDN6-Targeted Therapies
Understanding which patients may benefit from CLDN6-targeting immunotherapy and recognizing potential adverse effects is essential for oncology nurses.
Why Step-Up Dose With Bispecific Antibodies?
Karolina Faysman, NP, explains how step-up dosing is used to reduce CRS and ICANS with bispecific antibodies in multiple myeloma.
How to Manage ICANS in Patients With Hematologic Cancers
Nurses must stay up to date on novel agents and their toxicities to properly monitor for and manage immune effector cell-associated neurotoxicity syndrome.
Nurses, APPs Critical to Getting Oncology Patients Newer Therapies
The role of nurses and APPs is crucial to ensuring patients with cancer can receive newer therapies, shares David A. Braun, MD, PhD.
Patient Views on Skin-Related AEs May Affect Cancer Treatment Choices
Survey results show patients may overestimate dermatologic AEs from anti-cancer therapies, raising concerns for treatment adherence.
Managing Infection Risk With Bispecific Antibodies in Myeloma
Nurse practitioner Beth Faiman shares strategies to reduce infection risk in patients receiving bispecific antibodies for multiple myeloma.
Nurses Are Key to Reducing Opioid Use After Colorectal Surgery
Ronald Bleday, MD, discusses how nurses support a step-wise model to minimize opioid use after colorectal surgery while ensuring safe pain control.
Precision Supportive Care Individualizes Patient Experience
Catering supportive care to the individual being treated helps better meet the needs of each patient, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.
Transitioning to Community Care With Multiple Myeloma
Lisa Hwa Christenson, APRN, DNP, CNP, FAPO, outlines best practices for safely transitioning patients with multiple myeloma on bispecific antibodies to community care.
A Nurse’s Overview of First-Line Treatment for HR+ Metastatic Breast Cancer
Experts share advice on tailoring frontline treatment and managing toxicities for individuals with hormone receptor–positive metastatic breast cancer.
Current and Emerging ADCs Transforming Cancer Care
Kelsey Martin, APRN, AG-ACNP-BC, AOCNP, discusses current ADCs in breast, bladder, and lung cancer and highlights promising agents in development.
